American journal of nuclear medicine and molecular imaging最新文献

{"title":"Prediction of EGFR mutation status in lung adenocarcinoma based on ¹⁸F-FDG PET/CT radiomic features.","authors":"Jian-Ling Tan, Liang Xia, Su-Guang Sun, Hui Zeng, Di-Yu Lu, Xiao-Jie Cheng","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The earlier identification of EGFR mutation status in lung adenocarcinoma patients is crucial for treatment decision-making. Radiomics, which involves high-throughput extraction of imaging features from medical images for quantitative analysis, can quantify tumor heterogeneity and assess tumor biology non-invasively. This field has gained attention from researchers in recent years. The aim of this study is to establish a model based on ¹⁸F-FDG PET/CT radiomic features to predict the epidermal growth factor receptor (EGFR) mutation status of lung adenocarcinoma and evaluate its performance. 155 patients with lung adenocarcinoma who underwent ¹⁸F-FDG PET/CT scans and EGFR gene detection before treatment were retrospectively analyzed. The LIFEx packages was used to perform 3D volume of interest (VOI) segmentation manually on DICOM images and extract 128 radiomic features. The Wilcoxon rank sum test and least absolute shrinkage and selection operator (LASSO) regression algorithm were applied to filter the radiomic features and establish models. The performance of the models was evaluated by the receiver operating characteristic (ROC) curve and the area under the curve (AUC). Among the models we have built, the radiomic model based on ¹⁸F-FDG PET/CT has the best prediction performance for EGFR gene mutation status, with an AUC of 0.90 (95% CI 0.84~0.96) in the training set and 0.79 (95% CI 0.64~0.94) in the test set. In conclusion, we have established a radiomics model based on ¹⁸F-FDG PET/CT, which has good predictive performance in identifying EGFR gene mutation status in lung adenocarcinoma patients.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138457237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of tumor assessment between two PET systems using various indices: comparison between PET/CT and PET/MRI systems.","authors":"Hirotoshi Hotsumi,&nbsp;Shirou Ishii,&nbsp;Hiroki Suenaga,&nbsp;Shigeyasu Sugawara,&nbsp;Kenji Fukushima,&nbsp;Hiroshi Ito","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study aimed to determine the comparability of tumor-uptake indices of ¹⁸F-FDG in positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) PET/CT and PET/MRI were performed on 55 patients with confirmed primary malignancies. PET/CT preceded PET/MRI in all examinations. Accumulation of ¹⁸F-FDG in lesions and normal organs (brain, liver) was measured. Maximum and peak standardized uptake values (SUVs; SUV_max and SUV_peak, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) with margin thresholds of SUV of 50% (MTV_50%; TLG_50%, respectively) were measured as indices for comparison of measurements in tumors. Comparative indices with tumor SUV_max and liver ratio (TLR_max), brain ratio (TBR_max) were calculated. These indices were compared between PET/CT and PET/MRI examinations. The data measured using PET/CT and PET/MRI showed significant correlations for all tumor indices. The correlation was strongest for SUV_peak (r = 0.933), followed by TBR_max (r = 0.929); and the index ratio of (PET/CT)/(PET/MRI) data was close to 1.0 for TLR_max (1.00 ± 0.22) and TBR_max (1.01 ± 0.21), followed by MTV_50% (0.82 ± 0.33) and TLG_50% (1.18 ± 0.45). The values of all indices showed strong correlations between PET/CT and PET/MRI examinations. Among them, TLR_max, TBR_max, MTV_50%, and TLG_50% showed a close value and may be useful for comparison of tumor evaluation between two PET systems.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509291/pdf/ajnmmi0013-0156.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41095638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel technique of detecting inflammatory and osseous changes in the glenohumeral joint associated with patient age and weight using FDG- and NaF-PET imaging.","authors":"Peter Sang Uk Park,&nbsp;Lori Jia,&nbsp;William Y Raynor,&nbsp;Om H Gandhi,&nbsp;Mia Mijung Park,&nbsp;Thomas J Werner,&nbsp;Poul Flemming Høilund-Carlsen,&nbsp;Abass Alavi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>The glenohumeral (GH) joint is a classic ball-and-socket joint of the shoulder subject to various pathologies including osteoarthritis (OA). Degenerative changes of the OA evident on traditional imaging are proceeded by molecular changes, which if detected early could enhance disease prevention and treatment. In this study, we use ¹⁸F-FluoroDeoxyGlucose (FDG) and ¹⁸F-sodium-fluoride (NaF)-PET/CT to investigate the effects limb laterality, age, and BMI on the inflammation and bone turnover of the GH shoulder joint.</p><p><strong>Methods: </strong>FDG and NaF-PET/CT scans of 41 females (mean age of 43.9 ± 14.2 years) and 45 males (mean age of 44.5 ± 13.8 years) were analyzed with a semi-quantitative technique based on predefined region of interest.</p><p><strong>Results: </strong>There was greater FDG uptake in the left side of the GH joint compared to the right in both females (left: 0.79 ± 0.17, right: 0.71 ± 0.2; <i>P</i> < 0.0001) and males (left: 0.76 ± 0.19, right: 0.57 ± 0.18; <i>P</i> < 0.0001). We also observed a strong positive association between BMI and FDG uptakes in females (left: <i>P</i> < 0.0001, r = 0.71, right: <i>P</i> < 0.0001, r = 0.58) and males (left: <i>P</i> < 0.0001, r = 0.56, right: <i>P</i> < 0.0001, r = 0.64). Association between BMI and NaF uptake were found in males as well (left: <i>P</i> = 0.004, r = 0.42, right: <i>P</i> = 0.02, r = 0.35).</p><p><strong>Conclusion: </strong>Our study demonstrates the varying effect of limb laterality and BMI on FDG and NaF uptake at the GH joint. Adoption of molecular imaging will require future studies that correlate tracer uptake with relevant medical and illness history as well as degenerative change evident on traditional imaging.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509288/pdf/ajnmmi0013-0136.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41101926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and monitoring of large vessel vasculitides - a review article.","authors":"Mahshid Bahrami,&nbsp;Hossein Mohammadi,&nbsp;Hannaneh Mirgaloyebayat,&nbsp;Zahra Mohajeri,&nbsp;Pooya Fazeli,&nbsp;Azad Mojahedi,&nbsp;Ali Afsharirad,&nbsp;Reza Tavakoli,&nbsp;Amirhossein Sadeghian,&nbsp;Sayed Mohammad Amin Nourian","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the last two decades, advancements in positron emission tomography (PET) technology have increased the diagnostic accuracy of patients with large-vessel vasculitis (LVV). Numerous systematic reviews and meta-analyses have been conducted, and patients suspected of having LVV can be diagnosed earlier with 18F-FDG PET. Two subtypes, giant cell arteritis (GCA) and Takayasu arteritis (TA), will progress when their response to corticosteroids and enhanced immunosuppression is inadequate. In the majority of patients, disease activity cannot be monitored solely through laboratory procedures; consequently, glucose metabolism may be a source of potential biomarkers. In this article, we discuss the current state of 18F-FDG PET/CT imaging standards.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509293/pdf/ajnmmi0013-0127.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41108807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duodenal-type follicular lymphoma in ¹⁸F-FDG PET/CT imaging: a case report.","authors":"Wenpeng Huang,&nbsp;Fangfang Chao,&nbsp;Yushuo Peng,&nbsp;Xiaoyue Zhang,&nbsp;Qi Yang,&nbsp;Lele Song,&nbsp;Liming Li,&nbsp;Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Follicular lymphoma (FL) is a subtype of non-Hodgkin lymphoma (NHL) that is typically characterized by a slow-growing course. Duodenal-type follicular lymphoma (D-FL) was recently reclassified as a distinct variant. This subtype exhibits unique clinical and biological characteristics, which set it apart from other forms of FL. We report a case of a 36-year-old male patient with multiple, small, gray polypoid lesions in the descending duodenum which were detected by esophagogastroduodenoscopy. The pathological diagnosis was low-grade D-FL. ¹⁸F-FDG PET/CT was performed for staging and revealed the pancreas and peripheral lymph nodes were involved by FL, with a clinical IV stage. The patient underwent a bone marrow smear cytology, which revealed no bone marrow abnormalities, and excluded bone marrow involvement. He was treated with six cycles of chemotherapy using the R-CHOP regimen and reached complete remission.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509290/pdf/ajnmmi0013-0164.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41092161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model.","authors":"Oskar Vilhelmsson Timmermand,&nbsp;Marcella Safi,&nbsp;Bo Holmqvist,&nbsp;Joanna Strand","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We have previously investigated the biodistribution and therapy effect of a humanized monoclonal antibody targeting free prostate-specific antigen (fPSA) intended for theranostics of hormone-refractory prostate cancer. In the present study, we evaluated the off-target effect and different linear energy transfer (LET) radionuclides without the effect of PSA targeting by using an antibody with the same scaffold as previously used immunoconjugates but with random, non-specific, antigen binding region. This allows us to identify alterations generated by specific targeting and those related to passive bystander effects, such as enhanced permeability and retention (EPR). A control humanized IgG monoclonal antibody (hIgG1) and an isotype control IgG monoclonal antibody were conjugated with the chelator CHX-A\"-DTPA. The immunoconjugate was radiolabeled with either Lutetium-177 ([¹⁷⁷Lu]Lu) or Indium-111 ([¹¹¹In]In). A biodistribution study in mice carrying LNCaP xenografts, was performed to evaluate the non-specific uptake of [¹⁷⁷Lu]Lu-hIgG1 in tumors and normal organs. Further, therapy studies of [¹⁷⁷Lu]Lu and [¹¹¹In]In labeled IgG were performed in BALB/c mice carrying LNCaP xenografts. Tumor tissues of treated xenografts and control were sectioned and immunohistochemically stained for Ki67 and PSA. The highest tumor uptake for the [¹⁷⁷Lu]Lu-hIgG1 was seen at 72 hours (7.2±2 %IA/g), when comparing the tumor uptake of the fPSA targeting antibody to the non-specific antibody, the non-specific antibody contributes to half of the tumor uptake at 72 h. The liver uptake was 3.1±0.5 %IA/g at 24 h, 2.8±0.5 %IA/g at 72 h and 1.3±0.6 %IA/g at 120 h in LNCaP xenografts, which was approximately three times lower at 24 h and two times lower at 72 h than for the antibody with preserved targeting. Immunohistochemical labeling showed a reduction of PSA expression and a reduction of Ki67 labeled cells in the [¹¹¹In]In treated LNCaP tumors, compared to vehicle and [¹⁷⁷Lu]Lu treated mice. In conclusion, we found that specific targeting might negatively influence normal organ uptake when targeting secreted antigens. Furthermore, different energy deposition i.e. linear energy transfer of a radionuclide might have diverse effects on receptor expression and cell proliferation in tumors.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509292/pdf/ajnmmi0013-0147.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41102703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated radiosynthesis of [¹⁸F]FMPEP-<i>d</i>₂ for cannabinoid receptor PET imaging.","authors":"Huailei Jiang,&nbsp;Yan Guo,&nbsp;Otto Muzik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The cannabinoid subtype 1 receptor (CB1R) is highly expressed in the central nervous system and abnormalities in regional CB1R density are associated with neurodegenerative disorders. The PET tracer [¹⁸F]FMPEP-<i>d</i>₂ is an inverse CB1R agonist which was shown to be suitable for non-invasive PET imaging. In this work, we reported the fully automated radiosynthesis of [¹⁸F]FMPEP-<i>d</i>₂ on a Synthra RNplus research module. In a total synthesis time of 70 min, [¹⁸F]FMPEP-<i>d</i>₂ was obtained in 2.2 ± 0.1 GBq (n = 3) with excellent radiochemical and chemical purity. Quality control test showed that [¹⁸F]FMPEP-<i>d</i>₂ product meets all the release criteria for clinical patient use.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509289/pdf/ajnmmi0013-0171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41095337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke and molecular imaging: a focus on FDG-PET.","authors":"Cyrus Ayubcha, Aamir Amanullah, Krishna H Patel, Eric Teichner, Saket Gokhale, Ulysses Marquez-Valenzuela, Thomas J Werner, Abass Alavi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Stroke is the leading cause of disability worldwide, the second most common cause of dementia and the third leading cause of death. Though the etiology of stroke has been explored extensively, there remains open questions in the scientific and clinical study of stroke. Traditional imaging techniques, such as magnetic resonance imaging and computed tomography, have been applied extensively and remain mainstays in clinical practice. Nevertheless, positron emission tomography has proven to be a powerful molecular imaging tool in exploring the scientific aspects of neurological disease, and stroke remains an area of great interest. This review article examines the role of positron emission tomography in the study of stroke including its contributions to elaborating related pathophysiology and delving into possible clinical applications.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193198/pdf/ajnmmi0013-0051.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9503757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.","authors":"Shaun D. Grega, David X. Zheng, Q. Zheng","doi":"10.18060/26670","DOIUrl":"https://doi.org/10.18060/26670","url":null,"abstract":"Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality. Early detection of HCC is important since potentially curative therapies exist in the initial stages of HCC; no curative therapies exist for late-stage HCC. However, the initial detection of HCC remains challenging due to the lack of symptoms during the early stage of the disease. Other methods of screening and detecting HCC, including blood serum tests and conventional imaging methods, remain inadequate due to genetic differences between patients and the high background activity of liver tissues. Thus, there is a need for an accurate imaging agent for the diagnosis, staging, and prognosis of HCC. Glypican-3 (GPC3) is an oncofetal receptor responsible for regulating cell division, growth, and survival. GPC3 is a clinically relevant biomarker for imaging and therapeutics, as its expression is HCC tumor-specific and absent from normal and other pathological liver tissues. The development of novel GPC3-targeting imaging agents has encompassed three classes of biomolecules: peptides, antibodies, and aptamers. These biomolecules serve as constructs for diagnostic imaging (demonstrating potential as positron emission tomography [PET], single-photon emission tomography [SPECT], and optical imaging agents) and HCC treatment delivery. More than 20 unique ligands have been identified in the literature as showing specificity for the GPC3 receptor. Although several ligands are currently under clinical investigation as therapies for HCC, clinical translation of GPC3-targeting ligands as imaging agents is lacking. This review highlights the current landscape of ligands targeting GPC3 and describes their promising possibilities as imaging agents for HCC.","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45501803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rectal gastrointestinal stromal tumor case accompanied by elevated CEA mimicking rectal carcinoma on ¹⁸F-FDG PET/CT.","authors":"Zihao Tao,&nbsp;Sitong Wu,&nbsp;Zhao Chen,&nbsp;Yongkang Qiu,&nbsp;Lele Song,&nbsp;Qi Yang,&nbsp;Lin Nong,&nbsp;Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm arising from gastrointestinal tract and can be benign or malignant. Rectal GISTs are rare and have poor prognosis. We here reported an older male who presented with features of distending discomfort in the rectum and pain in the anus due to a large rectal tumor. Physical examinations detected a mass in the rectum without blood staining on the gloved finger. Carcinoembryonic antigen (CEA) was found to be slightly elevated and the prostate-specific antigen level was normal. ¹⁸F-FDG PET/CT showed a soft tissue density mass at the bottom of the pelvic, with an unclear boundary to the surroundings with the significantly increased FDG uptake (SUVmax 17.5). Although a rectal carcinoma was suspected based on the finding of PET/CT and CEA, the histopathological examination confirmed the diagnosis of the malignant GIST of the rectum. The patient was then treated with imatinib and on follow-up regularly. In this case, ¹⁸F-FDG PET/CT shows the advantage of visualizing both primary and metastatic lesions and provides valuable information for the diagnosis, staging, evaluation, and prognosis of GIST.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009467/pdf/ajnmmi0013-0026.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9122048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}